Oxford Biomedica PLC Hardman: Delivering commercial gene-therapy vector
March 31 2017 - 02:15AM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
31 March 2017
Hardman Research: Delivering commercial gene-therapy vector
Delivering commercial gene-therapy vector - OXB is a specialist
gene and cell therapy viral-vector biopharmaceutical company. It
offers vector manufacturing and development services, whilst
retaining its own proprietary therapeutic candidates. Above
service-fees, OXB will receive royalties on commercial products
developed with its LentiVector(R) platform: extensive IP,
facilities, and know-how for production and development of
lentivirus vectors to generate gene-based therapies. OXB intends to
out-license its five clinical candidates and to continue investment
in R&D. Bioprocessing royalties are likely to result in
significant upside potential in the near future.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/31.03.17-delivering-commercial-gene-therapy-vector.pdf
To contact us: Contacts:
Hardman & Co Dr Martin Hall
11/12 Tokenhouse mh@hardmanandco.com
Yard Dr Dorothea Hill
London dmh@hardmanandco.com
EC2R 7AS Dr Gregoire Pave
gp@hardmanabdco.com
Telephone: +44 20 7929 3399
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAJMMRTMBMJBBR
(END) Dow Jones Newswires
March 31, 2017 02:15 ET (06:15 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2023 to Mar 2024